April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Outcomes of Treatment of Pediatric CNV with Intravitreal Anti-angiogenic Agents: The Results of The KKESH International Collaborative Retina Study Group
Author Affiliations & Notes
  • J Fernando Arevalo
    Vitreoretinal Division, King Khaled Eye Specialist Hosp, Riyadh, Saudi Arabia
    Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
  • Igor Kozak
    Vitreoretinal Division, King Khaled Eye Specialist Hosp, Riyadh, Saudi Arabia
  • Ahmad M Mansour
    Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
  • Rocio I Diaz
    Charles Retina Institute, Memphis, TN
  • Jorge I Calzada
    Charles Retina Institute, Memphis, TN
  • Francesco Pichi
    University Eye Clinic, San Giuseppe Hospital, Milan, Italy
  • Vanessa Cruz-Villegas
    Department of Ophthalmology, University of Puerto Rico School of Medicine, San Juan
  • Manuel Diaz-Llopis
    Department of Ophthalmology, University of Valencia School of Medicine, Valencia, Spain
  • Roberto Gallego-Pinazo
    Department of Ophthalmology, University of Valencia School of Medicine, Valencia, Spain
  • Footnotes
    Commercial Relationships J Fernando Arevalo, ALCON LABORATORIES (C), ALCON LABORATORIES (R), IRIDEX (R), King Khaled Eye Specialist Hospital (F), NOVARTIS PHARMACEUTICALS CORP (R), Optos, Inc. (R), SECOND SIGHT LLC (C), SECOND SIGHT LLC (R), Springer SBM LLC (P); Igor Kozak, None; Ahmad Mansour, None; Rocio Diaz, None; Jorge Calzada, None; Francesco Pichi, None; Vanessa Cruz-Villegas, None; Manuel Diaz-Llopis, None; Roberto Gallego-Pinazo, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4961. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J Fernando Arevalo, Igor Kozak, Ahmad M Mansour, Rocio I Diaz, Jorge I Calzada, Francesco Pichi, Vanessa Cruz-Villegas, Manuel Diaz-Llopis, Roberto Gallego-Pinazo, ; Outcomes of Treatment of Pediatric CNV with Intravitreal Anti-angiogenic Agents: The Results of The KKESH International Collaborative Retina Study Group. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4961.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate safety and clinical results after the use of intravitreal anti-angiogenic agents for the treatment of choroidal neovascularization (CNV) in pediatric patients.

 
Methods
 

Retrospective multicenter study of a total of 45 eyes of 39 pediatric patients with CNV who were treated with intravitreal injection of anti-angiogenic agents (1.25 mg/0.05 ml bevacizumab [40 eyes] or 0.5 mg/0.05 ml ranibizumab [5 eyes]). Choroidal neovascularization due to various causes was clinically diagnosed and confirmed with imaging studies.

 
Results
 

There were 24 females and 15 males with group median age 13 years (range 3-17 years). Mean follow-up period was 12.8 months (range 3-60 months). The etiology of the CNV included idiopathic, uveitic, myopic CNV, and CNV associated with various macular dystrophies. Median logMAR visual acuity at presentation and last follow-up was 0.87 (Snellen equivalent 20/150) and 0.7 (Snellen equivalent 20/100), respectively which was statistically significant (p=0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes of this group (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse).

 
Conclusions
 

Intravitreal anti-angiogenic therapy for CNV in pediatric patients seems temporarily safe and effective in the majority of affected eyes. Due to the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.

 
 
Early frame fluorescein angiogram (left) shows macular lesion with surrounding hypofluorescence and additional hyporeflective foci superotemporally (white arrow). Late frame shows staining of the macular lesion, dark hypofluorescence of the surrounding ring and hypofluorescent foci of the additional superotemporal lesions (right).
 
Early frame fluorescein angiogram (left) shows macular lesion with surrounding hypofluorescence and additional hyporeflective foci superotemporally (white arrow). Late frame shows staining of the macular lesion, dark hypofluorescence of the surrounding ring and hypofluorescent foci of the additional superotemporal lesions (right).
 
Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 561 injection • 700 retinal neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×